These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 18413790)

  • 1. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
    Bonfils C; Kalita A; Dubay M; Siu LL; Carducci MA; Reid G; Martell RE; Besterman JM; Li Z
    Clin Cancer Res; 2008 Jun; 14(11):3441-9. PubMed ID: 18519775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group.
    Beckers T; Burkhardt C; Wieland H; Gimmnich P; Ciossek T; Maier T; Sanders K
    Int J Cancer; 2007 Sep; 121(5):1138-48. PubMed ID: 17455259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
    Arts J; Angibaud P; Mariën A; Floren W; Janssens B; King P; van Dun J; Janssen L; Geerts T; Tuman RW; Johnson DL; Andries L; Jung M; Janicot M; van Emelen K
    Br J Cancer; 2007 Nov; 97(10):1344-53. PubMed ID: 18000499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
    Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
    Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
    Buglio D; Mamidipudi V; Khaskhely NM; Brady H; Heise C; Besterman J; Martell RE; MacBeth K; Younes A
    Br J Haematol; 2010 Nov; 151(4):387-96. PubMed ID: 20880107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.
    Le Tourneau C; Siu LL
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1247-54. PubMed ID: 18616420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.
    Cao ZA; Bass KE; Balasubramanian S; Liu L; Schultz B; Verner E; Dai Y; Molina RA; Davis JR; Misialek S; Sendzik M; Orr CJ; Leung L; Callan O; Young P; Dalrymple SA; Buggy JJ
    Mol Cancer Ther; 2006 Jul; 5(7):1693-701. PubMed ID: 16891455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
    Buggy JJ; Cao ZA; Bass KE; Verner E; Balasubramanian S; Liu L; Schultz BE; Young PR; Dalrymple SA
    Mol Cancer Ther; 2006 May; 5(5):1309-17. PubMed ID: 16731764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
    Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
    PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
    Kakihana M; Ohira T; Chan D; Webster RB; Kato H; Drabkin HA; Gemmill RM
    J Thorac Oncol; 2009 Dec; 4(12):1455-65. PubMed ID: 20009910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
    Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
    Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
    Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Payne JE; Jenkins DA; Bonnefous C; Trotter C; Wang Y; Anzola JV; Milkova EL; Hoffman TZ; Dozier SJ; Wiley BM; Saven A; Malecha JW; Davis RL; Muhammad J; Shiau AK; Noble SA; Rao TS; Smith ND; Hager JH
    Mol Cancer Ther; 2008 May; 7(5):1054-65. PubMed ID: 18483295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
    Lu YS; Kashida Y; Kulp SK; Wang YC; Wang D; Hung JH; Tang M; Lin ZZ; Chen TJ; Cheng AL; Chen CS
    Hepatology; 2007 Oct; 46(4):1119-30. PubMed ID: 17654699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.
    Zhou N; Moradei O; Raeppel S; Leit S; Frechette S; Gaudette F; Paquin I; Bernstein N; Bouchain G; Vaisburg A; Jin Z; Gillespie J; Wang J; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Lu A; Rahil J; MacLeod AR; Li Z; Besterman JM; Delorme D
    J Med Chem; 2008 Jul; 51(14):4072-5. PubMed ID: 18570366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.